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G309 and S310 HER2 mutations are located in 
extracellular domain II region, which act as an epitope of 
pertuzumab and the dimerization arm. S310F, the most common 
mutation in the HER2 extracellular domain, can drive cancer 
without HER2 gene amplification. However, the effect of S310F 
mutation on the extracellular domain II poorly understood. In 
this study, the effects of G309 and S310 activating mutations 
on HER2 were evaluated using therapeutic antibodies and 
compared the dimerization of wild-type and S310F mutated 
HER2 with epidermal growth factor receptor (EGFR). G309A, 
G309E, S310F or S310Y mutations on HER2 resulted in the 
loss of binding activity of HER2 domain II binding antibody, 
pertuzumab, possibly due to structural change of HER2 domain 
II by the mutations. In addition, the phosphorylation of EGFR 
and HER2, and the viability of 5637 cells with S310F mutation 
were not affected by the pertuzumab. On the other hand, HER2 
domain IV binding antibody, trastuzumab, still had binding 
activity to HER2 even in the presence of the mutations. 
However, as trastuzumab is a HER2 homodimerization blocking 
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antibody, it did not affect the phosphorylation and viabilityof 
5637 cells. Surprisingly, phosphorylation of EGFR and HER2 
and the viability of 5637 cells were affected by EGFR targeted 
antibody, cetuximab, and EGFR or pan-HER TKIs (tyrosine 
kinase inhibitor) such as gefitinib or lapatinib. Additionally, we 
confirmed EGFR/HER2 and EGFR/HER2 S310F 
heterodimerization levels were similar on EGFR and HER2 
transfected cells. S310F missense mutation of HER2 is an 
activating mutation located on EGFR/HER2 dimerization arm. 
Even though the S310F mutation resulted in the structural 
change of HER2 domain II, the mutation did not affect the 
EGFR/HER2 heterodimerization. Therefore, EGFR/HER2 S310F 
heterodimerization was stillmainly formed in 5637 cell lines that 
are overexpressed with EGFR and harbor low levels of HER2 
S310F mutation. For these results, we suggest the use of EGFR 
targeted antibodies or TKIs treatments for EGFR-
overexpressed/low level HER2 S310F expressed cancer 
patients. 
 
Keywords: HER2, Mutation, Pertuzumab, TIR microscope, 
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HER2/ErbB2/Neu is a member of the human epidermal 
growth factor receptor (EGFR, HER) family of homologous 
transmembrane receptor tyrosine kinases. The HER family is 
composed of four receptors (EGFR and HER2–4/ErbB1–4) and 
a number of variants generated by alternative slicing. There are 
11 types of ligands reactive to HER family receptors, including 
those generated by alternative splicing1. The roles for these 
receptors and their ligands have been well described in many 
types of human cancers, including breast, colon, pancreatic, 
ovarian, brain, and lung cancers2. Binding of the ligand to EGFR 
or HER3/4 induces conformational changes in the proteins, 
facilitating receptor dimerization, which results in trans-
phosphorylation oftyrosine residues in the carboxy tail3. The 
phosphortyrosines are docking sites for the recruitment of 
downstream signaling proteins. Human epidermal growth factor 
receptor 2 (HER2) has no known ligand but forms heterodimers 
with other EGFR family members and activates downstream 
signaling through the phosphoinositide 3-kinase/AKT and 
MAPK pathways4. 
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Amplification/overexpression of HER2 is associated 
with cell transformation and oncogenesis5, is observed in 20–25% 
of breast cancers, and is associated with poor survival6. In 
breast cancer cells with HER2 gene amplification, HER2 
receptors exist on the cell surface as monomers, homodimers 
and heterodimers. The therapeutic antibody trastuzumab binds 
to extracellular domain IV and the epitope is P579-Q583, 
D592-F595 and K615-P625 residues. Trastuzumab cannot 
block ligand-induced HER2 heterodimers and has preferential 
activity against breast cancers driven by HER2 homodimers7,8. 
Meanwhile pertuzumab binds to extracellular domain II, D307-
V308, L317-H318 and K336-P337 residues. This sterically 
blocks a binding pocket necessary for receptor dimerization, 
and inhibit HER2 association with its partner receptors9. This 
property may explain why pertuzumab, unlike trastuzumab, is 
effective against a broad range of cancers which do not express 
HER2 at high levels10,11. Antibody drug conjugates (trastuzumab 
emtansine), and small molecule tyrosine kinase inhibitors 
(lapatinib, erlotinib, and neratinib) have also dramatically 
improved the outcomes of HER2-positive cancer patients12-15. 
Besides the amplification/overexpression of HER2, somatic 
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HER2 gene mutations have been detected in a range of human 
cancer types, including prostate neuroendocrine cancer, 
metastatic cutaneous squamous cell carcinoma, and bladder 
cancer16,17. Preclinical data suggest that functionally activating 
HER2 mutations may drive and maintain cancers in a manner 
analogous to HER2 gene amplification and those HER2 
mutations may similarly confer changes in sensitivity to HER2-
directed drugs18. 
There are more than 20 extracellular domain mutations 
detected in human cancer tissues (Table 1)8,18-37. Furthermore, 
26 additional extracellular domain mutations have been detected 
in various human cancer cell lines (Table 2). G309 and S310 
mutations of HER2 domain II are well-known activating 
mutations. Previous studies showed that the G309 mutation 
leaves unpaired cysteine residues (C299–C311), forming 
reduction-sensitive dimmers19. Likewise, the S310 mutation 
promotes non-covalent dimerization between neighboring 
molecules, promoting hyperphosphorylation of HER219. The 
NIH3T3 cells transfected with an expression vector encoding 
the S310F HER2 mutant were sensitive to trastuzumab, 
lapatinib, afatinib, and neratinib19. Clinically S310F is the most 
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frequently found mutation in the HER2 extracellular domain38. 
According to the cancer genomic cBioPortal database, S310F is 
the most commonly found mutation in the HER2 extracellular 
domain (0.4%)39,40. However,we did not find mutations in the 
genomic samples of Seoul National University Hospital. 
Two HER2-nonamplified breast cancer patients with 
S310F mutation were successfully treated with the trastuzumab 
alone or in combination with pertuzumab18,30. G309 and S310 
residues are located near the binding epitope for pertuzumab 
obscuring the reactivity of the antibody9. But the reactivity of 
pertuzumab as well as trastuzumab to the S310F mutant has not 
been previously reported. In this study, we prepared 
recombinant proteins corresponding to all reported G309 and 
S310 HER2 mutants and analyzed their interactions in 
Enzyme-linked immunosorbent assay (ELISA) with both 
trastuzumab and pertuzumab. We also used 5637 cells, an 
EGFR-amplified bladder cancer cell line expressing both S310F 
HER2 mutant and wild-type HER2 to analyze the downstream 
signaling of HER2 mutant and found that the S310F HER2 
mutant efficiently formed heterodimers with EGFR, which could 
not be inhibited by trastuzumab as well as pertuzumab. And 
5 
using single molecule level total internal reflection (TIR) 
microscopy, we confirmed that S310F mutant can form a 
heterodimer with EGFR at the molecular level.  
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L12R Breast Cancer ND Negative ND* [34]
A20T Lung cancer ND ND ND [23]
L49H Lung cancer ND Negative ND [20]
L49H Glioblastoma ND ND ND [19]
E139D Breast Cancer ND Negative ND [34]
E139G Breast Cancer ND Negative ND [34]
R157W Bladder cancer (MPUC) ND Negative ND [31]
T216S Lung cancer ND Negative ND [20]
T216S Glioblastoma ND ND High [19]
I263T Colorectal cancer ND Negative ND [35]
G309A Breast Cancer Activating Negative ND [26]
G309E Breast Cancer Activating Positive ND [23]
S310F Gastric cancer ND High [37]
S310F (2) Breast Cancer Negative High [25]
S310F Lung cancer Negative High [19]
S310F Breast Cancer Negative High [24]
S310F (2) Colorectal cancer Negative High [36]
S310F Breast Cancer Negative High [27]
S310F Lung cancer Positive High [21]
S310F Breast Cancer Negative High [28]
S310F (4) Bladder cancer (MPUC) Negative High [31]








S310F Breast Cancer Negative High [28]
S310F (2) Breast Cancer Positive High [29]
S310F Lung cancer ND High [22]
S310F Breast Cancer Negative High [30]
S310F (4) Breast Cancer Positive ND [34]
S310Y Lung cancer ND High [23]
S310Y Lung cancer ND High [19]
S310Y Colorectal cancer Positive High [20]
S310Y Bladder cancer (MPUC) Negative High [19]
C311R
and E321G
Lung cancer ND Negative ND [20]
C311R Glioblastoma ND ND Low [19]
N319D Lung cancer ND Negative ND [20]
N319D Glioblastoma ND ND ND [19]
E321G Glioblastoma ND ND Low [19]
D326G
and C334S
Lung cancer ND Negative ND [20]
D326G Glioblastoma ND ND Low [19]
C334S Glioblastoma ND ND ND [19]
A466T Colorectal cancer ND Negative ND [35]
A466V Breast Cancer Activating Negative High [34]
C515R Breast Cancer Activating Negative High [34]
T526A Breast Cancer Activating Negative High [34]
Activating















SW1271 S22N - Lung ND* ND
HEC59 R100W Endometrium ND ND
HEC108 T166M Endometrium ND ND









KM12 P230L Large intestine ND ND




HRT18 L313I Intestine ND ND
NCIH2110 N319Y Lung ND ND
HCC1359 T328S Lung ND ND











OC314 A386T Ovary ND ND
OC316 A386T Ovary ND ND
NCIN87 F425L Stomach ND ND















RL952 G518V Endometrium ND ND
NCIH1793 V541M Lung ND ND











Materials and Methods 
 
1. Expression and purification of recombinant 
fusion proteins 
Genes encoding the extracellular domain of wild-type 
HER2, wild-type HER3 and G309A, G309E, S310F, or S310Y 
HER2 mutants were chemically synthesized with SfiI restriction 
sites at the 5′ and 3′ ends (GenScript Biotech, Jiangsu, 
China). After restriction digestion with SfiI (New England 
Biolabs, Hertfordshire, UK), the genes were ligated into pCEP4 
vectors encoding either human Fc or Cκ, as described 
previously41,42. Genes encoding the scFv form of pertuzumab, 
trastuzumab, and cetuximab were also synthesized with SfiI 
restriction sites at the 5′ and 3′ ends (GenScript Biotech) 
and cloned into the human Cκ vector43-45. 
The expression vectors were then transfected into 
HEK293F cells (FreeStyle 293-F cells) using polyethylenimine 
(Sigma-Aldrich, St. Louis, MO, USA) as described previously46. 
The transfected cells were grown in FreeStyle 293 expression 
media (Invitrogen, Carlsbad, CA, USA) as described 
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previously47. The culture supernatants were purified by affinity 
chromatography using either Protein A or KappaSelect resin 
(GE Healthcare, Buckinghamshire, UK) following the 
manufacturer’s instructions. 
The purified recombinant proteins were subjected to 4–
12% NuPage bis-Tris gels (Invitrogen) according to the 
manufacturer’s instructions. After the electrophoresis, the gel 
was stained with Coomassie Brilliant Blue R-250 (Ameresco, 
Framingham, MA, USA). 
 
2. ELISA  
Recombinant wild-type HER2, wild-type HER3 or 
HER2 mutant extracellular domain-human Fc fusion proteins 
were coated overnight at 4°C on the wells of microtiter plates 
(Corning, Corning, NY, USA). The wells were blocked with 130 
μL of blocking buffer [3% bovine serum albumin (BSA) in 
phosphate-buffered saline (PBS)] for 1 h at 37°C. The plates 
were then incubated with recombinant pertuzumab or 
trastuzumab scFv- human Cκ fusion proteins serially diluted 
four-fold in blocking buffer for 2 h at 37°C. The plates were 
then washed with 150 μL of 0.05% Tween 20 in PBS (PBST) 
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for three times. Subsequently, horseradish peroxidase (HRP) 
conjugated anti-human Cκ light chain antibody(1:5,000; 
Millipore, Hayward, CA, USA) was added to each well. After 
incubation for 1 h at 37°C, the plates were washed. Finally, 50 
μL of 3,3′,5,5′-tetramethylbenzidine substrate solution 
(TMB) substrate was added and optical density was measured 
at 650 nm (LabSystems Diagnostics Oy, Vantaa, Finland). 
 
3. Cell culture 
The 5637and AU565 cells were obtained from the 
Korean Cell Line Bank (Seoul, Republic of Korea). The cells 
were grown in RPMI-1640 media (Welgene, Seoul, Republic of 
Korea) supplemented with 10% fetal bovine serum (Thermo 
Fisher Scientific, Gibco, Waltham, MA, USA) and 1% penicillin-
streptomycin (1,000 U/mL) (Thermo Fisher Scientific, Gibco).  
 
4. Sequencing of amplified HER2 gene fragments 
of5637cell 
Total RNA was isolated from the 5637 cells using 
TRIzol reagent (Invitrogen) as previously described48. After 
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cDNA was synthesized using a SuperScript III First-Strand 
Synthesis system (Invitrogen), the HER2 gene fragment 
encoding from N302 residue to R340 residue was amplified 
using specific primer sets (HER2 forward: 5′-
GCCTCCACTTCAACCACAGTGGC-3′ and HER2 reverse: 5′
-CTGTGATCTCTTCCAGAGTCTCAAAC-3′). The PCR 
conditions were as follows: preliminary denaturation at 95°C 
for 7 min, followed by 25 cycles of 30 s at 95°C, 30 s at 54°C, 
and 1 min at 72°C. The reaction was ended with an extension 
step for 5 min at 72°C.After agarose gel electrophoresis, the 
amplified DNA was extracted using the Qiagen Gel Extraction 
Kit according to the manufacturer ’ s instructions (Qiagen, 
Hilden, Germany) and subjected to Sanger sequencing 
(Macrogen, Seoul, Republic of Korea). 
 
5. Flow cytometry analysis 
The 5637 and AU565 cells (3 × 105 cells/well, Corning) 
were resuspended in 100 µL of flow cytometry buffer (1% BSA 
and 0.02% sodium azide in PBS), then incubated with cetuximab, 
pertuzumab, or trastuzumab scFv- human Cκ fusion proteins 
at a final concentration of 1 μM for 1 h at 37°C. The cells 
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were then washed twice with 1% (w/v) BSA in PBS and 
incubated with FITC-conjugated anti-human κ light chain 
antibody (Thermo Fisher Scientific) for 40 min at 37°C. After 
washing with flow cytometry buffer, the fluorescence intensity 
of cells was measured using a FACS Canto II (BD Bioscience, 
Heidelberg, Germany) and analyzed with FlowJo data analysis 
software (Threestar, OR, USA). Non-transfected HEK293T 
cell and cells transfected with EGFR-mCherry and HER2-
eGFP bicistronic expression vector were used as control cells 
and were analyzed in the same manner as above. 
 
6. Immunoprecipitation and immunoblot analyses 
The AU565 and 5637 cells (1 × 107 cells) were lysed 
in 100 μL of cold RIPA buffer (150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 
mM Tris-HCl, and 2 mM EDTA at pH 7.5) containing a 
protease inhibitor cocktail (Roche, Basel, Switzerland). 
Subsequently, 500 μL of the cell lysatewas incubated with 
either recombinant trastuzumab or pertuzumab scFv-human C
κ fusion protein with a final concentration of 100 μg/mL at 4°
C overnight with rotation. Then, 10 μL of KappaSelect resin 
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(GE Healthcare) was added to the lysate, followed by 
incubation at 4°C for 4 h with gentle rotations. After 
centrifugation for 3 min at 1,200 × g, the resin and 
supernatant were collected. The cell lysate, resin, and 
supernatant representing the same number of the cells were 
subjected to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE)as described above and transferred onto nitrocellulose 
membranes (Whatman, Dassel, Germany) using a transfer 
system as previously described49. Thereafter, the membrane 
was blocked with 5% skim milk (BD Biosciences, CA, USA) 
followed by incubation with rabbit anti-HER2 antibody (Cell 
Signaling Technology, Danvers, MA, USA) at 4°Covernight and 
with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1:5,000, 111-035-008; Jackson ImmunoResearch 
Laboratory, West Grove, PA, USA). After several washes with 
Tris-buffered saline and Tween [10 mM Tris-HCl, pH 7.5, 
150 mM NaCl, and 1% (v/v) Tween 20], the protein bands were 
visualized using Super Signal Pico West chemiluminescent 
substrate (#34080; Thermo Fisher Scientific)  and  a gel doc 
EZ system (Bio-Rad, Hercules, CA, USA). 
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7. Cell viability assay and immunoblotting 
The 5637 cells were seeded at a density of 5.5–10 × 
103/well in 96-well culture plates. After incubation for 24 h, 
cells were treated with 1 μM of cetuximab (Merck, Palo Alto, 
CA, USA), pertuzumab (Roche), trastuzumab (Roche), gefitinib 
(AstraZeneca, Cambridge, UK), or lapatinib (GlaxoSmithKline, 
Brentford, UK). After 96 h, the number of viable cells was 
determinedusing a Premix WST-1 kit (Takara, Kyoto, Japan) 
following the manufacturer ’ s protocol. For immunoblot 
analysis, 5637 cells were lysed in ice-cold RIPA buffer 
containing a protease inhibitor cocktail (Roche) and 
phosphatase inhibitor (Roche). The cell lysates were cleared by 
centrifugation for 10 min at 13,000 × g and the amount of 
protein in the supernatants was determined by a BCA assay 
(Pierce Biotechnology, Waltham, MA, USA). The proteins in the 
supernatants were separated by SDS-PAGE using 4–12% bis-
Tris gels (Invitrogen) as described aboveand transferred onto a 
nitrocellulose membrane. The membrane was blocked by 
preincubation in 5% BSA/0.2% TBST at room temperature for 
30 min and then incubated with anti-EGFR antibody (Cell 
Signaling Technology), anti-phospho-EGFR (Tyr 1068) 
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antibody (Cell Signaling Technology), anti-HER2 antibody 
(Cell Signaling Technology), anti-phospho-HER2 (Tyr 
1221/1222) antibody (Cell Signaling Technology), anti-PARP 
(Cell Signaling Technology), anti-cleaved PARP (Cell Signaling 
Technology), or anti-β-actin antibody (Cell Signaling 
Technology) for overnight at 4°C. After washing three times 
with 0.2% TBST, the membrane was incubated with either 
HRP-conjugated goat anti-rabbit IgG Fc antibody (#31463; 
Thermo Fisher Scientific) or HRP-conjugated goat anti-mouse 
IgG antibody (sc-2005; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) for 1 h at room temperature. The membrane was 
washed three times with TBST, and the bound antibody was 
visualized by addition of SuperSignal Pico West 
chemiluminescent substrate (#34080; Thermo Fisher Scientific) 
following the manufacturer’ s instructions. The Image Lab 
program (Biolab) was used to determine the intensity of bands. 
 
8. Single-molecular interaction analysis using total 
internal reflection fluorescence (TIRF) microscopy 
Single-molecular interaction analysis was performed as 
described in a previous study with appropriate modifications50. 
18 
Genes encoding fusion proteins composed of the extracellular 
domain of the EGFR fused with mCherry protein (EGFR-
mCherry) and that of wild-type HER2 fused with eGFP 
(HER2-eGFP)were ligated into a bicistronic expression vector. 
Another expression vector was prepared with the S310F 
mutant (S310F HER2-eGFP) replacing wild-type HER2. Then, 
these vectors were transfected into HEK293T cells (FreeStyle 
293-T cells). After culture at 37°C with 5% CO2 for 1 day, the 
cells were dissolved in lysis buffer (1% Triton X-100, 150 mM 
NaCl, 1 mM EDTA, 10% glycerol) with protease (P8340; 
Sigma-Aldrich) and phosphatase (P5726; Sigma-Aldrich) 
inhibitor cocktail. After centrifugation at 15,000 × g for 10 min 
at 4°C, the supernatant was collected. Recombinant mCherry 
(4999-100; Biovision, Milpitas, CA, USA) and eGFP (4993-
100; Biovision) protein standards were used to determine the 
concentration of fluorescently tagged proteins in the cell 
lysates. The fluorescence levels for recombinant eGFP and 
mCherry proteins of known concentrations (5–25 nM, five 
different concentration points) were measured using a 
fluorometer (Enspire 2300; Perkin-Elmer, San Jose, CA, USA) 
and were used to construct a calibration curve.  
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Detailed procedures of the flow chamber construction 
are described in previous studies51,52. The flow chamber was 
washed twice with 200 μL of PBS. Afterwards, 50 μL of 
NeutrAvidin solution(A2666; Invitrogen) was added to the flow 
chamber and was incubated for 5 min at room temperature. 
Subsequently, the flow chambers were washed twice followed 
by addition of diluted biotinylated polyclonal RFP antibody 
(34771; Abcam, Cambridge, UK) for 5 min at room temperature. 
This antibody was reported to be reactive to all RFP variants 
from Discosoma, including mCherry. After the flow chambers 
were washed again, cell lysates were added and incubated for 
10 min at room temperature. Finally, the flow chambers were 
washed with 0.1% lysis buffer/PBS. EGFR/HER2 heterodimers 
were then detected with a TIRF microscope equipped with a 
488-nm laser for eGFP detection. The images were recorded 
at 0.1 sec per frame, and 20 frames were recorded. To obtain a 
time-averaged image,three frames were averaged. EGFP spots 
were characterized from these time-averaged images. To 
obtain the intensity of eGFP spots, 10 time-averaged images 




1. The recombinant S310F mutant is not reactive 
to pertuzumab but binds to trastuzumab. 
A construct encoding the S310F HER2 extracellular 
domain fused to a human Fc domain of immunoglobulin heavy 
chain was prepared and cloned into a mammalian expression 
vector. For comparison, the expression vectors encoding the 
extracellular domains of all the other G309 and S310 mutants 
reported previously (G309A, G309E, S310F and S310Y HER2 
mutants) and those of wild-type HER2 and HER3 were also 
prepared. After transfection, the recombinant fusion proteins 
were purified from the culture supernatant using an affinity 
column reactive to human Fc. The extracellular domain of four 
mutants and wild-type HER2 was also prepared as a fusion 
protein of human Cκ through cloning into a mammalian 
expression vector, transfection and purification using an affinity 
column reactive to human Cκ from the culture supernatant. To 
check the purity, the recombinant fusion proteins were 
subjected to SDS-polyacrylamide gel electrophoresis and the 
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gel was stained. No band except the fusion protein was 
visualized. In non-reducing conditions, multimers of G309E 
HER2 mutant fusion proteins were visualized in both fusion 
protein forms (Figure 1). The purified recombinant Fc fusion 
proteins were then subjected to an ELISA to test reactivity to 
pertuzumab and trastuzumab (Figure 2). A microtiter plate was 
coated with the recombinant Fc fusion proteins, blocked, and 
incubated with either pertuzumab or trastuzumab expressed as 
recombinant scFv-human Cκ fusion protein. Then, the amount 
of bound antibody was determined using anti-human Cκ 
antibody conjugated to HRP. S310F mutants did not bind to 
pertuzumab but reacted with trastuzumab in a dose-dependent 
manner (Figure 3). Pertuzumab did not bind to the G309E, 
S310F, and S310Y HER2 mutants, but reacted with the S309A 
HER2 mutant with reduced affinity compared to that of the 
wild-type HER2. Trastuzumab bound to the wild-type HER2 








Figure 1. SDS-polyacrylamide gel electrophoresis analysis of 
recombinant G309 mutant extracellular domains fused with the 
human Fc or Cκ domain. The expression vectors encoding the 
fusion proteins were transfected into HEK293F cells. The 
recombinant proteins were purified from the culture 
supernatants using the affinity resin reactive to either Fc or 
human Cκ and subjected to 4%–12% (w/v) SDS-
polyacrylamide gel electrophoresis either with or without a 
reducing agent. After electrophoresis, the protein bands were 









Figure 2. Expression of recombinant anti-EGFR family 
antibodies. The human Cκ fusion anti-EGFR family antibodies 














Figure 3. Reactivity of G309 and S310 HER2 mutants to 
pertuzumab and trastuzumab. Recombinant G309 and S310 
mutant, wild-type HER2, or wild-type HER3 human Fc fusion 
protein was coated onto the wells of microtiter plates. The plate 
was blocked and subjected to incubation with (a) recombinant 
pertuzumab scFv-human Cκ fusion protein, or (b) 
trastuzumab scFv-human Cκ fusion protein at varying 
concentrations. Wild-type HER3 human Fc fusion protein was 
used as a negative control, because it does not bind to either 
antibody. The amount of bound antibody was determined using 
HRP-conjugated human Cκ light chain antibody and 




2. A bladder cancer cell line, 5637, expresses both 
wild-type HER2 and S310F mutant. 
We searched literatures to identify a human cell line 
expressing the S310F mutant and found that bladder cancer cell 
line 5637 expressed the mutant. To test the allelic expression 
of the S310F HER2 mutant in the 5637 cell line, we extracted 
total RNA from the cells and prepared cDNA. A HER2 gene 
fragment including the S310 residue was amplified by PCR 
using specific primers and subjected to Sanger sequencing. A 
representative sequence chromatogram is shown in Fig. 2. We 
found that both the wild-type (nucleotide C) and the mutant 
(nucleotide T) peaks co-existed at the corresponding 
nucleotide position (Figure 4). To check the expression of the 
wild-type and mutant HER2 on the cell surface, we used 
recombinant trastuzumab and pertuzumab scFv-Cκ fusion 
proteins to avoid the possible non-specific interaction through 
Fc regions of IgG and Fc receptors on the cell and performed 
flow cytometric analyses. As expected, pertuzumab as well as 
the trastuzumab scFv-Cκ fusion protein reacted with the 5637 
cells (Figure 5), which proved the presence of the wild-type 
HER2 on the cell surface of 5637 cells. 
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To confirm the expression of the S310F HER2 mutant in 
5637 cells, we used immunoprecipitation experiments. We 
hypothesized that if the cells expressed the S310F HER2 
mutant, it would not be immunoprecipitated by pertuzumab and 
would remain in the cell lysate. To determine the saturable 
amount of pertuzumab for immunoprecipitation experiments, we 
screened cell lines expressing higher amounts of HER2 than 
5637 cells and identified AU565 cells (Figure 5). The amount 
of pertuzumab and trastuzumab scFv-Cκ fusion protein 
guaranteeing the immunoprecipitation of all of HER2 in AU565 
cell lysates was then determined (Figure 6). This 
predetermined amount of scFv-human Cκ fusion protein was 
then incubated with the 5637 cell lysate, with added affinity 
resin reactive to Cκ. After centrifugation, pellets and 
supernatants were collected. Thereafter, the cell lysate, 
precipitated resin, and supernatant representing the same 
number of 5637 cells were subjected to SDS-polyacrylamide 
gel electrophoresis and immunoblot analysis using anti-HER2 
antibody reactive to the HER2 domain III. Trastuzumab scFv-C
κ fusion protein immunoprecipitated nearly all HER2 molecules 
in the 5637 cell lysate, but pertuzumab scFv-human Cκ fusion 
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protein immunoprecipitated only a fraction of HER2 (Figure 6). 
With this observation, we concluded that 5637 cells expressed 









Figure 4. Sanger sequencing of 5637 cell HER2 gene. A 
representative sequence chromatogram showing the presence 
of two transcripts encoding wild-type HER2 and the S310F 







Figure 5. Expression of HER2 and EGFR in 5637 and AU565 
cells. Flow cytometry analysis of two cancer cell lines 
assessing their reactivity to cetuximab, pertuzumab, and 
trastuzumab. The cells were incubated with individual antibody 
using the recombinant scFv-human Cκ fusion protein. The 
amount of bound antibody was determined using 





Figure 6. Immunoprecipitations of HER2 in AU565 and 5637 
cell lysates using trastuzumab and pertuzumab. Cell lysates 
were incubated with trastuzumab or pertuzumab scFv- human 
Cκ fusion protein followed by affinity resin reactive to human 
kappa light chain. After centrifugation, the amount of HER2 in 
the supernatant, resin, and cell lysate representing the same 
number of cells was determined by immunoblot analysis using 
anti-HER2 antibody.  
* IP = Immunoprecipitated 
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3. EGFR activates S310F HER2 mutant in 5637 
cell.    
We tested the effects of anti-HER2 agents on 5637 cell 
proliferation and the level of HER2 phosphorylation at Y1221 
and Y1222 residues. The cells were incubated with pertuzumab, 
trastuzumab and lapatinib for 96 h, lysed and subjected to 
SDS-PAGE and immunoblot analysis using anti-phospho-
HER2 antibody. In parallel, the number of viable cells after the 
incubation was determined. Inhibiting the ligand-independent 
dimerization of wild-type and S310F HER2 mutant by 
trastuzumab did not reduce the cell proliferation or HER2 
phosphorylation(Figure 7, 8, 9). Inhibiting the ligand-
dependent dimerization of wild-type HER2 by pertuzumab also 
failed to show any effect (Figure 7, 8, 9). However, lapatinib 
inhibited the cell proliferation and reduced HER2 
phosphorylation (Figure 7, 8, 9(b)). Because lapatinib inhibits 
the catalytic activity of both the EGFR and HER2, we then 
tested the effects of cetuximab and gefitinib, and both 
effectively inhibited the cell proliferation and reduced the levels 
of phosphorylated HER2and EGFR (Figure 7, 8, 9). The 
apoptosis induced by anti-EGFR and anti-HER2 agents was 
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also determined (Figure 8, 9(b)). In accordance with the cell 
proliferation data, only cetuximab, gefitinib, and lapatinib 
induced the cleavage of PARP (Figure 8, 9(c)). Based on these 
data, we concluded that EGFR induced phosphorylation of 






Figure 7. Cell growth inhibition by anti-HER2 and anti-EGFR 
agents. Cells were treated with HER2 or EGFR inhibitors for 96 
h. Cell viability was measured by WST-1 kit as described in 
materials and methods. Relative cell viability as a percent was 
determined as ((absorbance in each treatment set – 
absorbance in untreated set) / absorbance in non-treated set X 
100). Results represent the mean ± SD obtained from 
experiments performed in three independent experiments. NT; 
not treated, Cet; Cetuximab, Ptz; Pertuzumab, Gef; Gefitinib, 






Figure 8. Inhibition of 5637 cell proliferation and receptor 
activation by anti-HER2 and anti-EGFR agents. Cells were 
treated with HER2 or EGFR inhibitors for 96 h. The cell lysate 
was subjected to immunoblot analysis to visualize the relative 
phosphorylation level of EGFR and HER2 and the level of 
cleaved PARP. NT; not treated, Cet; Cetuximab, Ptz; 
Pertuzumab, Gef; Gefitinib, Lap; Lapatinib, DMSO; dimethyl 












Figure 9. Relative phosphorylation level of EGFR (a) and HER2 
(b) and the level of cleaved PARP (c). Each these levels of 
figure 8 were quantified by densitometry and plotted, 
individually. *P < 0.005. NT; not treated, Cet; Cetuximab, Ptz; 
Pertuzumab, Gef; Gefitinib, Lap; Lapatinib, DMSO; dimethyl 
sulfoxide, PARP; poly (ADP-ribose) polymerase. 
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4. Single-molecular interaction analysis 
demonstrated that he S310F HER2 mutant formed 
heterodimers with the EGFR.  
Single molecule interaction analysis was performed to 
determine whether the HER2 S310F mutant formed a 
heterodimer with the EGFR. We constructed a bicistronic 
mammalian expression vector encoding EGFR-mCherry and 
HER2 S310F-eGFP fusion proteins. For comparison, we also 
prepared another expression vector encoding EGFR-mCherry 
and wild-type HER2-eGFP fusion proteins. After transfection 
of the expression vector into HEK293T cells, the expression of 
EGFR, HER2 S310F mutant, and wild-type HER2 were 
confirmed by flow cytometry analysis; using recombinant 
cetuximab, trastuzumab and pertuzumab scFv-human Cκ 
fusion proteins, the HEK293T cells showed basal expression of 
EGFR and HER2 (Figure 10). The transfected cells showed 
significantly increased reactivity to cetuximab and trastuzumab. 
In HEK293T cells transfected with the expression vector 
encoding EGFR-mCherry and HER2 S310F-eGFP, the 
reactivity with pertuzumab was significantly lower compared to 
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the cells transfected with that encoding EGFR-mCherry and 
wild-type HER2-eGFP.  
After transfection, the cells were allowed to grow for 24 
h and then lysed. The level of EGFR-mCherry and wild-type 
and HER2 S310F-eGFP in the cell lysate was determined by 
measuring the fluorescence intensity. After a calibration curve 
was prepared using recombinant mCherry and eGFP protein 
standard with a florometer, the ratios of EGFR-mCherry vs 
wild-type HER2-eGFP and EGFR-mCherry vs HER2 S310F-
eGFP in the cell lysates were determined to be 1:2.14 and 
1:2.98, respectively. For single molecule interaction analysis, 
the lysate was subjected to a flow chamber coated with anti-
mCherry antibody. Using the TIRF microscope, eGFP spots 
were identified and their intensity was determined and summed. 
The eGFP spot intensity summation value was increased in a 
dose-dependent manner as the concentration of EGFR-
mCherry injected into the flow cell was increased in both the 
cell lysates of wild-type HER2-eGFP and HER2 S310F-eGFP 
transfectants (Figure 11). Considering the ratio of wild-type 
HER2-eGFP and HER2 S310F-eGFP vs EGFR-mCherry in the 
cell lysates of the two transfectants, the ratio of eGFP vs 
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mCherry in the HER2 S310F-eGFP transfectants was not 
significantly different from that of the wild-type HER2-eGFP 
transfectants (Figure 11). Two additional independent 
experiments yielded similar results. Based on these 
observations, we concluded that HER2 S310F interacted with 
the EGFR and its efficiency was comparable to that of the EGFR 





Figure 10. Bicistronic vector transfection which encoding either 
EGFR-mCherry and wild-type HER2-eGFP or EGFR-
mCherry and S310F HER2-eGFP fusion proteins into 
HEK293T cell. After transfection, the cell surface expression 
of EGFR and HER2 or HER2 was checked by flow cytometry 
analysis using cetuximab, pertuzumab, and trastuzumab in the 







Figure 11. Single-molecular interaction analysis for the S310F 
mutant and EGFR heterodimerization. The transfected HEK 
293T cell lysates were subjected to a flow chamber coated with 
anti-mCherry antibody. Then, the summed intensity of eGFP 
spots was measured and plotted. Results represent the mean ± 





After the initiation of the Cancer Genome Anatomy 
Project, new genetic alterations and new driver events were 
found in human cancers53. Somatic mutations of HER2 have 
been identified in a wide range of solid tumors, including breast, 
lung, colorectal, bladder, gastric, and cervical cancers54-59. 
HER2 activating mutations have beenidentified mostly in the 
kinase domain. C515R, T526A, G776R, L755S, L869R, R897G, 
and P1074S mutations were reported to increase 
phosphorylation levels of HER2. D769H and V777L mutations 
increased the phosphorylation of both HER2 and EGFR26,60. 
L755S and V777L were the most studied mutations in clinical 
cases61,62. Cells with HER2 L775S mutation showed increased 
levels of phospho-EGFR, -HER2, and -HER326. Patients with 
the HER2 L755S mutation were resistant to trastuzumab and 
lapatinib treatment, and a non-small cell lung cancer patient 
with HER2 N813D mutations was resistant to afatinib63,64. HER2 
positive metastatic colorectal cancer patients with HER2 T784G 
mutation did not respond to cetuximab therapy65. A recent 
study showed that cells with the HER2 L755S mutation were 
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resistant to lapatinib66. HER2 activating mutations were also 
found on the extracellular domain. Seven mutations, including 
G309 and S310 mutations, were found to increase the 
phosphorylation level of HER2 (Table 1)31,61. However, the 
mechanism of how these extracellular mutations increase the 
phosphorylation of HER2 has not been clarified. 
In our study, ligand-independent HER2 dimerization 
blocking antibody, trastuzumab, did not inhibit the 
phosphorylation of HER2 in 5637 cells (Figure 7), although it 
bound to the S310F mutant as well as the wild-type HER2 
(Figure 3b). Trastuzumab treatment also did not hinder the 
proliferation of the cells (Figure 8). This observation proved 
that either S310F mutant or wild-type HER2 can be activated 
without forming heterodimer or homodimers among the mutant 
and wild-type HER2. Because 5637 cells overexpress the 
EGFR, we hypothesized that the S310F mutant or wild-type 
HER2 formed heterodimers with the EGFR. As expected, the 
ligand binding-blocking antibody, cetuximab, almost completely 
abolished the phosphorylation of not only EGFR but also HER2 
(Figure 7). As a ligand-dependent HER2 heterodimerization 
blocking antibody, pertuzumab did not inhibit the 
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phosphorylation of HER2 (Figure 7), while it bound to wild-
type HER2 (Figure 3a), EGFR-mediated phosphorylation 
should occur on the S310F mutant HER2. In this study, we 
were unable to determine the level of wild-type and S310F 
mutant in 5637 cells at the protein level; however, the limited 
amount of wild-type HER2 compared to the S310F mutant 
might be the reason why pertuzumab is not effective. To 
determine whether the S310F mutant retained affinity for the 
EGFR, we performed single molecule interaction analyses using 
a TIRF microscope as described previously50. The S310F HER2 
mutant showed an affinity equivalent to that of wild-type HER2 
in the formation of EGFR/HER2 complexes (Figure11). 
In this study, we confirmed the loss or reduction of 
pertuzumabreactivity to G309 and S310 mutated HER2 proteins 
(Figure 1a). Complementary determining region 3 (CDR3) of 
pertuzumab heavy chain makes hydrophobic and hydrogen bond 
contacts with residues K333 and H318 of HER29. Therefore, 
mutations on G309 and S310 would induce critical structural 
changes on the epitope of pertuzumab. Interestingly, 
pertuzumab showed reduced binding activity to G309A mutated 
proteins but no reactivity to the G309E mutated proteins. The 
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loss of binding activity could be explained by the structural 
difference between the two mutated amino acids; alanine and 
glutamic acid. G309 is located close to the C299-C311 disulfide 
bond67. While both glycine and alanine have a small nonpolar 
side chain, the glutamic acid has a long and charged side chain, 
influencing the structure of the HER2 domain II by breaking the 
disulfide bond. This hypothesis was tested by using SDS-
polyacrylamide gel electrophoresis of the mutated recombinant 
HER2 proteins. G309E mutated protein formed multimers in 
non-reducing conditions, while the wild-type and G309A 
mutated HER2 proteins formed monomers (Figure 1). This 
observation was in agreement with that of a previous study 
reporting that the G309E HER2 mutant formed homodimers 
under non-reducing conditions in SDS-polyacrylamide gel 
electrophoresis analysis, which could be resolved by reducing 
agents19.These results indicate that the use of pertuzumab in 
combination with trastuzumab has no additional effect on 
patients with HER2 amplification if they have G309 or S310 
mutations. 
Our study showed that a HER2 S310F mutation 
inducedstructuralchangesin domain II of HER2, abolishing its 
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reactivity to pertuzumab, but its ability to form EGFR/HER2 
dimers was not affected. HER2 heterodimerization with ligand-
bound HERs was through a domain II-mediated dimerization 
interface68. In contrast, HER2 heterodimerization with ligand-
free HERs may be mainly involved in domain IV69. After 
activation of EGFR, trastuzumab failed to reduce the 
phosphorylation level of the EGFR bound to HER270. Meanwhile, 
pertuzumab reduced the phosphorylation level of EGFR bound 
to HER271. The retained reactivity of S310F HER2 mutant to 
EGFR observed in our study suggested the unaffected structure 
of HER2 domain II on the interface of EGFR/HER2 heterodimer. 
C213, H215, and E243 residues of HER2 that are located on the 
top of the dimerization arm,are reported to stabilize the 
heterodimer by hydrogen bonding and salt bridges, and hence 
HER2 S310F mutation may not have affected the 
heterodimerization72. 
The effects of HER2 S310F dimerization with other 
molecules can be determined from the results of cell 
proliferation assays, using a combination of cetuximab and 
trastuzumab (Figure 7). Combination cetuximab-trastuzumab 
treatment reduced cell proliferation in 5637 cells, in contrast to 
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only cetuximab-treated cells. Because cetuximab-blocked 
HER2 S310F monomer can form dimers with neighboring 
molecules, trastuzumab can form dimers with neighboring 
molecules, trastuzumab can block this dimerization, resulting in 
reduced cell proliferation. Not only can the dimerization arm 
serve as a “hand”for EGFR/HER2 heterodimerization, but 
also for HER2/HER2 homodimerization and other HER2 
heterodimerization73,74. Thus, the S310F mutation is expected 
to have no effect on any other forms of dimerization. We tried 
to determine how the level of homodimerization changes with 
the S310F mutation but did not proceed. Single-molecule 
interaction analysis using a TIRF microscope is a method of 
measuring interactions of a eGFP-labeled molecule with a 
mCherry-labeled molecule. To measure S310F HER2 
homodimerization, two HER2 genes with S310F mutations must 
be labeled with mCherry and eGFP. However, the probability 
that mCherry-labeled and eGFP-labeled HER2 proteins would 
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HER2의 도메인 2에 위치한 G309와 S310은 수용기 
활성화 돌연변이로 S310F 돌연변이를 가지는 환자들은 HER2의 
증폭 없이도 암을 발생시킨다고 알려져 있다. 
이 연구에서는 HER2 도메인 2에 위치하며 활성화 
돌연변이로 알려진 G309A, G309E, S310F, S310Y가 HER2의 
세포 밖의 도메인에 결합하는 트라스투주맙과 퍼투주맙 항체와의 
결합에 어떠한 영향을 미치는지 확인하였다. 먼저, ELISA로 
결합력을 확인한 결과, 돌연변이가 있는 HER2 단백질에는 도메인 
4에 항원결정기를 가지는 트라스투주맙 항체가 결합을 하였지만, 
HER2 도메인 2에 항원결정기를 가지는 퍼투주맙 항체의 경우 
G309A 돌연변이를 가지는 HER2에만 결합을 하였다. 세포 
표면에서의 HER2 도메인 2 돌연변이에 의한 영향을 확인하기 
위하여 5637 이라는 HER2의 S310이 페닐알라닌으로 돌연변이가 
생기고 EGFR이 과발현 되어있는 방광암 세포주를 찾아 
연구하였다. 리간드-독립적 HER2 동형이량체 결합을 막는 
트라스투주맙 항체는 5637 세포주에 발현되어있는 HER2 수용기 
활성을 억제하지 못하였다. 반면, EGFR에 결합하는 세툭시맙 
항체와 TKI (tyrosine kinase inhibitor)인 제피티닙에 의하여 
HER2의 인산화가 감소되었고 성장이 크게 줄어들었다. 이는 
64 
5637 세포주에 존재하는 HER2가 주로 과발현 되어있는 EGFR과 
이형이량체 결합을 형성하고 있다고 예상할 수 있다.S310F 
돌연변이가 HER2가 EGFR과의 이형이량체 결합력에 영향을 
미치지 않는다는 것을 확인하기 위하여 TIRF microscope 실험을 
진행하였고, 이를 통하여 S310F 돌연변이를 가지는 HER2와 
돌연변이를 가지지 않는 야생형 HER2는 EGFR와의 이형이량체 
결합 정도와 비슷하다는 것을 확인하였다. 
위의 연구를 통하여 S310F 돌연변이를 가지는 HER2는 
문제없이 EGFR과 이형이량체 결합을 하여 활성화 되었으며, 이는 
HER2에 결합하는 트라스투주맙과 퍼투주맙 항체에 의하여 억제할 
수 없다는 것을 확인하였다. 이 결과는 S310F 돌연변이를 가지는 
HER2가 발현 되어있고 EGFR이 과발현 되어있는 암을 가지는 
환자들의 항체와 TKI 치료에 가이드라인을 제시할 수 있을 
것이라고 예상된다. 
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